Prolonged-Release Fampridine Treatment and Walking Ability and Balance in Patients with Multiple Sclerosis: Results of the Randomized, Double-Blind MOBILE Study

被引：0
作者：
Lycke, Jan
Short, Christine
Gasperini, Claudio
Hupperts, Raymond
McNeil, Manjit
Medori, Rossella
Mehta, Lahar
Elkins, Jacob
机构：
来源：
NEUROLOGY | 2014年 / 83卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：E36 / E36
页数：1
相关论文
共 50 条
  • [21] Treatment patterns and costs among patients with multiple sclerosis treated with prolonged-release fampridine in Germany
    Lee, A.
    Liu, Y.
    Gleissner, E.
    Prosser, C.
    Kinter, E.
    Landsman-Blumberg, P.
    Braun, S.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 670 - 670
  • [22] Fampridine Prolonged Release: A Review in Multiple Sclerosis Patients with Walking Disability
    Kim, Esther S.
    DRUGS, 2017, 77 (14) : 1593 - 1602
  • [23] Prolonged-Release Fampridine Treatment and Walking Speed in Japanese Patients with MS: Design of the Multicentre, Double-Blind, Randomised, Placebo-Controlled MOTION-JAPAN Study.
    Saida, T.
    Yokoyama, K.
    Masaki, K.
    McNeill, M.
    Mehta, L. R.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (03) : 423 - 423
  • [24] Relationship between Heat Intolerance and Response to Prolonged-Release Fampridine in Patients with Multiple Sclerosis
    Ziemssen, Tjalf
    Berger, Thomas
    Potts, James
    Putzki, Norman
    Goodman, Andrew
    NEUROLOGY, 2012, 78
  • [25] A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder
    Munizza, C.
    Olivieri, L.
    Di Loreto, G.
    Dionisio, P.
    CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (09) : 1703 - 1713
  • [26] Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study
    Garfinkel, Doron
    Zorin, Mariana
    Wainstein, Julio
    Matas, Zipora
    Laudon, Moshe
    Zisapel, Nava
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2011, 4 : 307 - 313
  • [27] Cost-effectiveness analysis of prolonged-release fampridine to treat walking disability of multiple sclerosis in China
    Zhao, Xinran
    Yang, Han
    Wei, Tian
    Zhao, Jin
    Liu, Jun
    Huang, Zhe
    Zhu, Lin
    Zhao, Yinan
    Li, Wei
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2022, 11 (14) : 1057 - 1069
  • [28] BUDGET IMPACT OF ORAL PROLONGED-RELEASE FAMPRIDINE FOR MANAGEMENT OF WALKING DISABILITY ASSOCIATED WITH MULTIPLE SCLEROSIS IN TAIWAN
    Lee-Grossman, C. W.
    Alexopoulos, S. T.
    Murphy, D. R.
    VALUE IN HEALTH, 2012, 15 (07) : A675 - A676
  • [29] A guide to treating gait impairment with prolonged-release fampridine (Fampyra®) in patients with multiple sclerosis
    Ramio-Torrenta, L.
    Alvarez-Cermeno, J. C.
    Arroyo, R.
    Casanova-Estruch, B.
    Fernandez, O.
    Garcia-Merino, J. A.
    Hernandez, M. A.
    Izquierdo, G.
    Martinez-Yelamos, S.
    Meca, J.
    Moral, E.
    Olascoaga, J.
    Prieto, J. M.
    Saiz, A.
    NEUROLOGIA, 2018, 33 (05): : 327 - 337
  • [30] QUALITY OF LIFE AMONG PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH PROLONGED-RELEASE FAMPRIDINE 10 MG TABLETS FOR WALKING IMPAIRMENT
    Liu, Y.
    McNeill, M.
    Lee, A.
    Zhong, J.
    Mehta, L. R.
    VALUE IN HEALTH, 2014, 17 (07) : A401 - A402
12345